Celltrion, Inc. Share Price

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 10/12/2025			5-day change	1st Jan Change
185,700.00 ^KRW	-0.85%		+1.31%	+3.00%

12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI

Last Transcript: Celltrion, Inc.

Celltrion, Inc. - Analyst/Investor Day

11-27

More transcripts

Analysts' recommendations: Celltrion, Inc.

03-17

Nomura Adjusts Celltrion's Price Target to KRW240,000 From KRW230,000, Keeps at Buy

More recommendations

Press Releases: Celltrion, Inc.

11-05	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
10-14	Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	AQ
09-30	FDA Approves Biocon's Denosumab Biosimilars	AQ
06-16	Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	PU
05-12	Celltrion : Investor Presentation May & June 2025	PU

More press releases

News in other languages: Celltrion, Inc.

09-24	Wall Street : La Fed ne peut pas sauver tout le monde
09-23	Wall Street: la confiance en suspens jusqu'à la prise de parole de Powell
03-10	US-Behörde FDA lässt Biosimilar für Roche-Mittel Xolair zu
12-18	MÄRKTE ASIEN/Mehrheitlich fester - Fusionsgespräche stützen Autowerte
11-21	MÄRKTE ASIEN/Knapp behauptet - Tokio schwächer

More news

Managers and Directors: Celltrion, Inc.

Manager	Title	Age	Since
Wu-Sung Ki CEO	Chief Executive Officer	-	19/03/2015
Ho-Seop Lee DFI	Director of Finance/CFO	50	-
Sung-Han Lee CMP	Compliance Officer	43	-

Director	Title	Age	Since
Jung-Jin Seo CHM	Chairman	68	-
Dong-Il Kim BRD	Director/Board Member	67	16/07/2008
Joseph Lee BRD	Director/Board Member	67	16/07/2008

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CELLTRION, INC.	-0.85%	+1.31%	+11.36%	+16.84%	27.64B
LONZA GROUP AG	-0.70%	-2.85%	+2.79%	+17.60%	47.04B
IQVIA HOLDINGS INC.	+2.23%	-1.90%	+9.70%	+6.90%	37.96B
BEONE MEDICINES AG	+1.25%	-4.49%	+72.10%	+63.80%	35.71B
MEDPACE HOLDINGS, INC.	+3.06%	-2.73%	+63.99%	+172.51%	15.8B
REVOLUTION MEDICINES, INC.	+0.09%	+0.24%	+64.69%	+227.50%	15.06B
ICON PUBLIC LIMITED COMPANY	+2.52%	-1.02%	-13.94%	-4.57%	14.19B
TEMPUS AI, INC.	-1.07%	+0.21%	+66.82%	-	13.36B
IONIS PHARMACEUTICALS, INC.	-0.29%	-3.92%	+105.51%	+109.68%	12.74B
ASCENDIS PHARMA A/S	+2.34%	+0.37%	+55.19%	+71.90%	12.3B
Average	+1.12%	-1.44%	+43.82%	+75.80%	23.18B
Weighted average by Cap.	+0.88%	-1.80%	+34.90%	+55.85%

See all sector performances

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,680

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/12/25	185,700.00 ₩	-0.85%	307,749
09/12/25	187,300.00 ₩	+0.11%	348,992
08/12/25	187,100.00 ₩	+2.07%	630,756
05/12/25	183,300.00 ₩	+0.38%	476,038
04/12/25	182,600.00 ₩	-0.38%	467,290

End-of-day quote Korea S.E., December 09, 2025

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Investor

Global

Quality

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

185,700.00KRW

Average target price

223,458.07KRW

Spread / Average Target

+20.33%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Capitalization	40,631B 27.64B 23.73B 22.19B 20.73B 38.25B 2,484B 41.62B 257B 100B 1,178B 104B 102B 4,321B	P/E ratio 2025 *	52.2x	P/E ratio 2026 *	34.5x
Enterprise value	41.64B 28.33M 24.32M 22.75M 21.25M 39.21M 2.55B 42.66M 264M 103M 1.21B 106M 104M 4.43B	EV / Sales 2025 *	10.1x	EV / Sales 2026 *	8.42x
Free-Float	70.87%	Yield 2025 *	0.4%	Yield 2026 *	0.43%

12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI
11-26	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	CI
11-19	Celltrion to invest up to $478 million to expand US factory in response to tariffs	RE
11-18	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	CI
11-18	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	CI
11-14	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Prime Medicine Q3 net loss narrows	RE
10-30	U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	CI
10-22	Celltrion to sell 746 million won worth of own shares	RE
10-21	Celltrion's Q3 Operating Income, Sales Rise	MT
10-20	Wellscare Signs A Memorandum of Understanding with Celltrion Canada	CI
10-17	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.	CI

1 day	-0.85%
1 week	+1.31%
Current month	+0.05%
1 month	+6.97%
3 months	+9.43%
6 months	+14.49%
Current year	+3.00%

1 week	181,000	188,800
1 month	174,100	203,500
Current year	144,615.38	203,500
1 year	144,615.38	203,500
3 years	119,963.37	220,695.97
5 years	119,963.37	336,673.13
10 years	54,514.52	341,497.26

	2025 *	2026 *
Net sales	4,140B 2.82B 2.42B 2.26B 2.11B 3.9B 253B 4.24B 26.22B 10.22B 120B 10.57B 10.34B 440B	4,933B 3.36B 2.88B 2.69B 2.52B 4.64B 302B 5.05B 31.24B 12.17B 143B 12.59B 12.33B 525B
Net income	817B 556M 477M 446M 417M 769M 49.94B 837M 5.17B 2.02B 23.67B 2.08B 2.04B 86.88B	1,229B 836M 718M 671M 627M 1.16B 75.15B 1.26B 7.78B 3.03B 35.62B 3.14B 3.07B 131B
Net Debt	1,013B 689M 591M 553M 517M 953M 61.91B 1.04B 6.41B 2.5B 29.34B 2.58B 2.53B 108B	921B 626M 538M 503M 470M 867M 56.31B 943M 5.83B 2.27B 26.69B 2.35B 2.3B 97.96B

Celltrion, Inc. Share Price

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Valuation: Celltrion, Inc.

Chart: Celltrion, Inc.

Latest news: Celltrion, Inc.

Last Transcript: Celltrion, Inc.

Analysts' recommendations: Celltrion, Inc.

Press Releases: Celltrion, Inc.

News in other languages: Celltrion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celltrion, Inc.

ETFs: Celltrion, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise